title: Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.
abstract: Optimal treatment of anaplastic oligodendroglial tumors (AOT) in elderly patients is debatable. We report a retrospective study of 44 consecutive patients aged 70 years or older [median age: 74 years; median Karnofsky performance status (KPS): 70] treated with up-front chemotherapy using temozolomide (TMZ) at conventional doses until tumor progression. O(6)-methylguanine-DNA methyltransferase promoter (MGMTP) methylation was assessed in 38 patients. Of the 41 evaluable patients, partial response (PR) was seen in 13 (32%) patients, 17 (41%) patients achieved stable disease, while the disease progressed in 11 (27%) patients. Median progression-free survival (PFS) and overall survival (OS) were 6.9 and 12.4 months, respectively. Hematotoxicity grades 3-4 occurred in nine patients (20%). MGMTP was methylated in 50% of patients and was associated with both longer PFS (8.7 versus 5.7 months, P = 0.01) and longer OS (16.1 versus 12.4 months, P = 0.05). The rate of responders to chemotherapy was similar in MGMTP-methylated (38%) and in MGMTP-unmethylated patients (31%), but duration of response was significantly longer in responders with methylated MGMTP than in responders with unmethylated MGMTP (16.1 versus 9.6 months, P = 0.0004). This study demonstrates that a substantial number of elderly patients with AOT can achieve prolonged survival with up-front chemotherapy using TMZ. Further investigation is needed to determine whether this treatment is preferable to initial radiation therapy.
authors.affiliation: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital, 75013, Paris, France.
authors.forename: François
authors.initials: F
authors.lastname: Ducray
authors.forename: Monica Sierra
authors.initials: MS
authors.lastname: del Rio
authors.forename: Catherine
authors.initials: C
authors.lastname: Carpentier
authors.forename: Dimitri
authors.initials: D
authors.lastname: Psimaras
authors.forename: Ahmed
authors.initials: A
authors.lastname: Idbaih
authors.forename: Caroline
authors.initials: C
authors.lastname: Dehais
authors.forename: Gentian
authors.initials: G
authors.lastname: Kaloshi
authors.forename: Karima
authors.initials: K
authors.lastname: Mokhtari
authors.forename: Sophie
authors.initials: S
authors.lastname: Taillibert
authors.forename: Florence
authors.initials: F
authors.lastname: Laigle-Donadey
authors.forename: Antonio
authors.initials: A
authors.lastname: Omuro
authors.forename: Marc
authors.initials: M
authors.lastname: Sanson
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Delattre
authors.forename: Khê
authors.initials: K
authors.lastname: Hoang-Xuan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000235:genetics; D045643:DNA Repair Enzymes / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic / Q000235:genetics; D012189:Retrospective Studies; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000235:genetics
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004273:DNA, Neoplasm; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide